![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0815.png)
Conclusion
•
DIBH implementation in lymphoma very succesful
•
Protocol in lung cancer patients ongoing
•
Clear dosimetric benefit, even when using VMAT/IMRT
•
Ressource investment: the ”sore points” are
PET scanning time
IGRT
And even then, they remain very manageable !